nodes	percent_of_prediction	percent_of_DWPC	metapath
Dapiprazole—Risperidone—DRD4—conduct disorder	0.29	0.684	CrCbGaD
Dapiprazole—Risperidone—HTR2A—conduct disorder	0.134	0.316	CrCbGaD
Dapiprazole—ADRA1D—Monoamine GPCRs—DRD4—conduct disorder	0.0399	0.0693	CbGpPWpGaD
Dapiprazole—ADRA1D—Amine ligand-binding receptors—DRD4—conduct disorder	0.0335	0.0582	CbGpPWpGaD
Dapiprazole—ADRA1B—Monoamine GPCRs—DRD4—conduct disorder	0.0331	0.0575	CbGpPWpGaD
Dapiprazole—ADRA1A—Monoamine GPCRs—DRD4—conduct disorder	0.0294	0.0511	CbGpPWpGaD
Dapiprazole—ADRA1B—Amine ligand-binding receptors—DRD4—conduct disorder	0.0278	0.0483	CbGpPWpGaD
Dapiprazole—ADRA1D—Monoamine GPCRs—HTR2A—conduct disorder	0.026	0.0452	CbGpPWpGaD
Dapiprazole—ADRA1A—Amine ligand-binding receptors—DRD4—conduct disorder	0.0247	0.0429	CbGpPWpGaD
Dapiprazole—ADRA1D—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0219	0.038	CbGpPWpGaD
Dapiprazole—ADRA1B—Monoamine GPCRs—HTR2A—conduct disorder	0.0216	0.0375	CbGpPWpGaD
Dapiprazole—ADRA1A—Monoamine GPCRs—HTR2A—conduct disorder	0.0192	0.0333	CbGpPWpGaD
Dapiprazole—ADRA1B—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0182	0.0315	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCRs, Other—DRD4—conduct disorder	0.0177	0.0308	CbGpPWpGaD
Dapiprazole—ADRA1A—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0161	0.028	CbGpPWpGaD
Dapiprazole—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0118	0.0205	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCRs, Other—HTR2A—conduct disorder	0.0116	0.0201	CbGpPWpGaD
Dapiprazole—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00978	0.017	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR ligand binding—CGA—conduct disorder	0.00897	0.0156	CbGpPWpGaD
Dapiprazole—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00868	0.0151	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.0077	0.0134	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR ligand binding—CGA—conduct disorder	0.00744	0.0129	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR ligand binding—CGA—conduct disorder	0.00661	0.0115	CbGpPWpGaD
Dapiprazole—ADRA1D—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0066	0.0115	CbGpPWpGaD
Dapiprazole—ADRA1D—G alpha (q) signalling events—HTR2A—conduct disorder	0.0065	0.0113	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00639	0.0111	CbGpPWpGaD
Dapiprazole—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00581	0.0101	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00568	0.00986	CbGpPWpGaD
Dapiprazole—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00548	0.00951	CbGpPWpGaD
Dapiprazole—ADRA1B—G alpha (q) signalling events—HTR2A—conduct disorder	0.00539	0.00937	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR downstream signaling—CGA—conduct disorder	0.00507	0.0088	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00502	0.00872	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR ligand binding—DRD4—conduct disorder	0.00502	0.00872	CbGpPWpGaD
Dapiprazole—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00486	0.00844	CbGpPWpGaD
Dapiprazole—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00482	0.00838	CbGpPWpGaD
Dapiprazole—ADRA1A—G alpha (q) signalling events—HTR2A—conduct disorder	0.00479	0.00832	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling by GPCR—CGA—conduct disorder	0.0046	0.00799	CbGpPWpGaD
Dapiprazole—ADRA1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0043	0.00747	CbGpPWpGaD
Dapiprazole—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00429	0.00744	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR downstream signaling—CGA—conduct disorder	0.00421	0.00731	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00417	0.00724	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR ligand binding—DRD4—conduct disorder	0.00417	0.00724	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling by GPCR—CGA—conduct disorder	0.00382	0.00663	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR downstream signaling—CGA—conduct disorder	0.00374	0.00649	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0037	0.00643	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR ligand binding—DRD4—conduct disorder	0.0037	0.00643	CbGpPWpGaD
Dapiprazole—ADRA1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00357	0.0062	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling by GPCR—CGA—conduct disorder	0.00339	0.00589	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR ligand binding—HTR2A—conduct disorder	0.00328	0.00569	CbGpPWpGaD
Dapiprazole—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00317	0.00551	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR downstream signaling—DRD4—conduct disorder	0.00284	0.00493	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR ligand binding—HTR2A—conduct disorder	0.00272	0.00472	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—CGA—conduct disorder	0.00272	0.00472	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling by GPCR—DRD4—conduct disorder	0.00258	0.00448	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR ligand binding—HTR2A—conduct disorder	0.00242	0.0042	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR downstream signaling—DRD4—conduct disorder	0.00236	0.00409	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—CGA—conduct disorder	0.00226	0.00392	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—WASF1—conduct disorder	0.00218	0.00378	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling by GPCR—DRD4—conduct disorder	0.00214	0.00372	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR downstream signaling—DRD4—conduct disorder	0.00209	0.00363	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—CGA—conduct disorder	0.002	0.00348	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling by GPCR—DRD4—conduct disorder	0.0019	0.0033	CbGpPWpGaD
Dapiprazole—ADRA1D—GPCR downstream signaling—HTR2A—conduct disorder	0.00185	0.00322	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—WASF1—conduct disorder	0.00181	0.00314	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling by GPCR—HTR2A—conduct disorder	0.00168	0.00292	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—WASF1—conduct disorder	0.00161	0.00279	CbGpPWpGaD
Dapiprazole—ADRA1B—GPCR downstream signaling—HTR2A—conduct disorder	0.00154	0.00267	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—DRD4—conduct disorder	0.00152	0.00264	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling by GPCR—HTR2A—conduct disorder	0.0014	0.00242	CbGpPWpGaD
Dapiprazole—ADRA1A—GPCR downstream signaling—HTR2A—conduct disorder	0.00137	0.00237	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—DRD4—conduct disorder	0.00126	0.00219	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling by GPCR—HTR2A—conduct disorder	0.00124	0.00215	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—DRD4—conduct disorder	0.00112	0.00195	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—HTR2A—conduct disorder	0.000994	0.00173	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—HTR2A—conduct disorder	0.000825	0.00143	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—HTR2A—conduct disorder	0.000733	0.00127	CbGpPWpGaD
Dapiprazole—ADRA1D—Signaling Pathways—EP300—conduct disorder	0.000526	0.000914	CbGpPWpGaD
Dapiprazole—ADRA1B—Signaling Pathways—EP300—conduct disorder	0.000437	0.000759	CbGpPWpGaD
Dapiprazole—ADRA1A—Signaling Pathways—EP300—conduct disorder	0.000388	0.000674	CbGpPWpGaD
